Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Goodwill (2016 - 2025)

Integra Lifesciences Holdings' Goodwill history spans 17 years, with the latest figure at $615.2 million for Q3 2025.

  • For Q3 2025, Goodwill changed N/A year-over-year to $615.2 million; the TTM value through Sep 2025 reached $615.2 million, changed N/A, while the annual FY2024 figure was $1.1 billion, 3.93% up from the prior year.
  • Goodwill for Q3 2025 was $615.2 million at Integra Lifesciences Holdings, roughly flat from $616.4 million in the prior quarter.
  • Across five years, Goodwill topped out at $1.1 billion in Q4 2024 and bottomed at $94.1 million in Q2 2021.
  • The 5-year median for Goodwill is $1.0 billion (2021), against an average of $790.1 million.
  • The largest annual shift saw Goodwill increased 8.7% in 2021 before it rose 1.6% in 2023.
  • A 5-year view of Goodwill shows it stood at $1.0 billion in 2021, then rose by 2.51% to $1.0 billion in 2022, then grew by 1.6% to $1.1 billion in 2023, then increased by 3.93% to $1.1 billion in 2024, then tumbled by 43.92% to $615.2 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Goodwill are $615.2 million (Q3 2025), $616.4 million (Q2 2025), and $1.1 billion (Q4 2024).